Clinical Trials Browser

Withdrawn × Solid Tumors × tislelizumab × Clear all

NCT05644626 2023-11-29

Safety, Pharmacokinetics and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab in Participants With Solid Tumors in Chinese Participants

Phase 1 Withdrawn

Other solid neoplasm

Solid Tumors